India - English - Central Drugs Standard Control Organization

mission res. - nimesulide,dextropropoxyphene hcl.,paracetamol - tab - 100,32.5,325;mg - 10

India - English - Central Drugs Standard Control Organization

jagsonpal - dicyclomine hcl.,dextropropoxyphene hcl.,paracetamol - cap - 10,65,400;mg - 10

India - English - Central Drugs Standard Control Organization

concept - dicyclomine hcl.,dextropropoxyphene hcl.,paracetamol - tab - 10,65,500;mg - 10

Australia - English - Department of Health (Therapeutic Goods Administration)

abbvie pty ltd - ritonavir -

Australia - English - Department of Health (Therapeutic Goods Administration)

canvale holdings pty ltd - borax,calcium citrate,cholecalciferol,hydroxyapatite,magnesium oxide - heavy,manganese amino acid chelate,phytomenadione,zinc gluconate -

Australia - English - Department of Health (Therapeutic Goods Administration)

amdipharm mercury australia pty ltd - auranofin, quantity: 3 mg - tablet, film coated - excipient ingredients: titanium dioxide; maize starch; lactose monohydrate; magnesium stearate; iron oxide yellow; microcrystalline cellulose; hypromellose; purified water; sodium starch glycollate; propylene glycol; ethanol - indications as at 14 november 2000: adjunctive treatment of active classical or definite rheumatoid arthritis in adults who have an insufficient therapeutic response to, or are intolerant of, an adequate trial of a baseline therapeutic program, including among other measures, full doses of one or more non-steroidal anti-inflammatory drugs. ridaura is not indicated in non-rheumatoid arthropathies such as osteoarthrosis. ridaura should be added to a comprehensive baseline therapeutic program.

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - moclobemide 150mg - film coated tablet - 150 mg - active: moclobemide 150mg excipient: ethylcellulose hypromellose iron oxide yellow lactose monohydrate macrogol 6000 magnesium stearate maize starch povidone purified talc sodium starch glycolate titanium dioxide - latest regulatory activity

New Zealand - English - Medsafe (Medicines Safety Authority)

viatris limited - moclobemide 300mg - film coated tablet - 300 mg - active: moclobemide 300mg excipient: ethylcellulose hypromellose lactose monohydrate macrogol 6000 magnesium stearate maize starch povidone purified talc sodium starch glycolate titanium dioxide - latest regulatory activity

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - ritonavir 100mg - film coated tablet - 100 mg - active: ritonavir 100mg excipient: calcium hydrogen phosphate colloidal silicon dioxide copovidone opadry white 16b18449 sodium stearyl fumarate sorbitan laurate - norvir is indicated for use in combination with appropriate antiretroviral agents or as monotherapy if combination therapy is inappropriate, for the treatment of hiv-1 infection in adults and children aged 12 years and older. for persons with advanced hiv disease, the indication for ritonavir is based on the results for one study that showed a reduction in both mortality and aids defining clinical events for patients who received ritonavir. median duration of follow-up in this study was 6 months. the clinical benefit from ritonavir for longer periods of treatment is unknown. for persons with less advanced disease, the indication is based on changes in surrogate markers in controlled trials of up to 16 weeks duration.

New Zealand - English - Medsafe (Medicines Safety Authority)

abbvie limited - ritonavir 80 mg/ml - oral solution - 80 mg/ml - active: ritonavir 80 mg/ml excipient: caramel citric acid ethanol peppermint oil polyoxyl 35 castor oil propylene glycol purified water saccharin sodium sunset yellow fcf - norvir is indicated for use in combination with appropriate antiretroviral agents or as monotherapy if combination therapy is inappropriate, for the treatment of hiv-1 infection in adults and children aged 12 years and older. for persons with advanced hiv disease, the indication for ritonavir is based on the results for one study that showed a reduction in both mortality and aids defining clinical events for patients who received ritonavir. median duration of follow-up in this study was 6 months. the clinical benefit from ritonavir for longer periods of treatment is unknown. for persons with less advanced disease, the indication is based on changes in surrogate markers in controlled trials of up to 16 weeks duration.